Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats.
第一作者:
Ekaterina A,Lesovaya
第一单位:
Department of Chemical Carcinogenesis, Blokhin Cancer Research Center, Moscow, Russia.
作者:
主题词
衰老(Aging);动物(Animals);抗生素类, 抗肿瘤(Antibiotics, Antineoplastic);疾病模型, 动物(Disease Models, Animal);用药计划表(Drug Administration Schedule);非那特利(Finasteride);男(雄)性(Male);钠米医学(Nanomedicine);前列腺(Prostate);前列腺增生(Prostatic Hyperplasia);大鼠(Rats);大鼠, Wistar(Rats, Wistar);西罗莫司(Sirolimus);舒必利(Sulpiride);TOR丝氨酸-苏氨酸激酶(TOR Serine-Threonine Kinases);睾酮(Testosterone)
DOI
10.18632/oncotarget.3929
PMID
25991667
发布时间
2021-12-03
- 浏览33

Oncotarget
9718-27页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文